Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-12-19 Sale | 2024-12-20 4:15 pm | Climb Bio Inc. | CLYM | Pimblett Emily CHIEF ACCOUNTING OFFICER | 1,235 | $2.02 | $2,495 | 36,329 (Direct) | View |
| 2024-09-20 Sale | 2024-09-20 9:53 pm | Eliem Therapeutics Inc. | ELYM | Pimblett Emily CHIEF ACCOUNTING OFFICER | 1,191 | $8.1791 | $9,741 | 37,564 (Direct) | View |
| 2024-07-19 Sale | 2024-07-23 5:04 pm | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 129,206 | $7.6505 | $988,495 | 31,317 (Direct) | View |
| 2024-07-17 Sale | 2024-07-19 11:12 am | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 41,783 | $6.9285 | $289,492 | 160,523 (Direct) | View |
| 2024-07-16 Sale | 2024-07-17 6:11 pm | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 50,000 | $7.13 | $356,500 | 202,306 (Direct) | View |
| 2024-07-12 Sale | 2024-07-16 6:14 pm | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 92,377 | $7.0425 | $650,563 | 252,306 (Direct) | View |
| 2024-07-09 Sale | 2024-07-11 8:45 pm | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 105,931 | $6.9526 | $736,500 | 344,683 (Direct) | View |
| 2024-07-05 Sale | 2024-07-09 4:46 pm | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 12,342 | $7.06 | $87,135 | 450,614 (Direct) | View |
| 2024-07-03 Sale | 2024-07-03 2:42 pm | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 50,000 | $6.76 | $338,000 | 473,154 (Direct) | View |
| 2024-06-27 Purchase | 2024-07-01 9:29 pm | Eliem Therapeutics Inc. | ELYM | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund L.P. RA Capital Nexus Fund II L.P. RA Capital Nexus Fund III L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 13,008,546 | $3.84 | $49,952,817 | 5,417,638 (Indirect) | View |
| 2024-06-20 Sale | 2024-06-21 2:57 pm | Eliem Therapeutics Inc. | ELYM | Pimblett Emily CHIEF ACCOUNTING OFFICER | 1,245 | $7.2145 | $8,982 | 38,755 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-12-18 Exercise | 2024-12-20 4:15 pm | N/A N/A | Climb Bio Inc. | CLYM | Pimblett Emily CHIEF ACCOUNTING OFFICER | 5,000 | $0 | 36,329 (Direct) | View |
| 2024-11-11 Option Award | 2024-11-12 5:47 pm | N/A 2034-11-10 | Climb Bio Inc. | CLYM | WILLIAMS DOUGLAS E Director | 26,291 | $0 | 26,291 (Direct) | View |
| 2024-09-18 Exercise | 2024-09-20 9:53 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Pimblett Emily CHIEF ACCOUNTING OFFICER | 5,000 | $0 | 37,564 (Direct) | View |
| 2024-08-26 Option Award | 2024-08-26 5:47 pm | N/A 2034-08-25 | Eliem Therapeutics Inc. | ELYM | Kaplan Brett Chief Operating Officer | 542,500 | $0 | 542,500 (Direct) | View |
| 2024-07-01 Exercise | 2024-07-03 2:42 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 7,649 | $0.0002 | 473,154 (Direct) | View |
| 2024-07-01 Exercise | 2024-07-03 2:42 pm | N/A 2031-02-25 | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 7,649 | $0 | 473,154 (Direct) | View |
| 2024-06-27 Option Award | 2024-07-01 9:29 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund L.P. RA Capital Nexus Fund II L.P. RA Capital Nexus Fund III L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 5,259,872 | $0 | 5,417,638 (Indirect) | View |
| 2024-06-26 Option Award | 2024-06-28 6:14 pm | N/A 2034-06-25 | Eliem Therapeutics Inc. | ELYM | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund L.P. RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 10,000 | $0 | 10,000 (Indirect) | View |
| 2024-06-26 Option Award | 2024-06-28 6:09 pm | N/A 2034-06-25 | Eliem Therapeutics Inc. | ELYM | Levin Andrew David Executive Chairman | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 5:26 pm | N/A 2034-06-25 | Eliem Therapeutics Inc. | ELYM | Rosenberg Adam Joseph Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 5:23 pm | N/A 2034-06-25 | Eliem Therapeutics Inc. | ELYM | Dunn Judith Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 5:13 pm | N/A 2034-06-25 | Eliem Therapeutics Inc. | ELYM | Tate Simon Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 5:09 pm | N/A 2034-06-25 | Eliem Therapeutics Inc. | ELYM | Ratcliffe Liam Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-06-27 Option Award | 2024-06-27 7:05 pm | N/A 2034-06-26 | Eliem Therapeutics Inc. | ELYM | Brennan Aoife President and CEO | 825,000 | $0 | 825,000 (Direct) | View |
| 2024-06-27 Option Award | 2024-06-27 7:03 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Thomas Stephen Basil Director | 204,282 | $0 | 204,282 (Direct) | View |
| 2024-06-18 Exercise | 2024-06-21 2:57 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Pimblett Emily CHIEF ACCOUNTING OFFICER | 5,000 | $0 | 38,755 (Direct) | View |
| 2024-04-05 Exercise | 2024-04-08 5:33 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 17,847 | $0.0002 | 533,353 (Direct) | View |
| 2024-04-05 Exercise | 2024-04-08 5:33 pm | N/A 2031-02-25 | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 17,847 | $0 | 533,353 (Direct) | View |
| 2024-03-18 Exercise | 2024-03-20 4:33 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Pimblett Emily CHIEF ACCOUNTING OFFICER | 40,000 | $0 | 40,000 (Direct) | View |
| 2023-09-20 Exercise | 2024-03-04 11:07 am | N/A N/A | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 15,297 | $0.0002 | 533,353 (Direct) | View |
| 2023-09-20 Exercise | 2024-03-04 11:07 am | N/A 2030-02-03 | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 20,728 | $0 | 533,353 (Direct) | View |
| 2023-09-20 Exercise | 2024-03-04 11:07 am | N/A N/A | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D AND CSO | 5,431 | $0.002 | 533,353 (Direct) | View |
| 2023-05-18 Option Award | 2023-05-22 5:22 pm | N/A 2033-05-17 | Eliem Therapeutics Inc. | ELYM | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund L.P. RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 10,000 | $0 | 10,000 (Indirect) | View |
| 2023-05-18 Option Award | 2023-05-22 5:13 pm | N/A 2033-05-17 | Eliem Therapeutics Inc. | ELYM | Tate Simon Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-05-18 Option Award | 2023-05-22 5:11 pm | N/A 2033-05-17 | Eliem Therapeutics Inc. | ELYM | Ratcliffe Liam Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-05-18 Option Award | 2023-05-22 5:08 pm | N/A 2033-05-17 | Eliem Therapeutics Inc. | ELYM | Dunn Judith Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-05-18 Option Award | 2023-05-22 5:05 pm | N/A 2033-05-17 | Eliem Therapeutics Inc. | ELYM | Rosenberg Adam Joseph Director | 10,000 | $0 | 188,100 (Direct) | View |
| 2023-05-18 Option Award | 2023-05-22 5:02 pm | N/A 2033-05-17 | Eliem Therapeutics Inc. | ELYM | Levin Andrew David Executive Chairman | 10,000 | $0 | 10,000 (Direct) | View |
Ownership | 2023-03-21 10:21 am | N/A 2031-04-26 | Eliem Therapeutics Inc. | ELYM | Pimblett Emily Chief Accounting Officer | 0 | $0 | 95,000 (Direct) | View |
| 2023-03-10 Exercise | 2023-03-14 5:04 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D and CSO | 61,191 | $0.0002 | 533,353 (Direct) | View |
| 2023-03-10 Exercise | 2023-03-14 5:04 pm | N/A 2030-02-03 | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D and CSO | 316,410 | $0 | 533,353 (Direct) | View |
| 2023-03-10 Exercise | 2023-03-14 5:04 pm | N/A N/A | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D and CSO | 255,219 | $0.002 | 533,353 (Direct) | View |
| 2022-10-31 Option Award | 2022-11-02 7:11 pm | N/A 2032-10-30 | Eliem Therapeutics Inc. | ELYM | Morisset Valerie EVP, R&D and CSO | 170,000 | $0 | 320,322 (Direct) | View |
| 2022-10-31 Option Award | 2022-11-02 7:09 pm | N/A 2032-10-30 | Eliem Therapeutics Inc. | ELYM | Azelby Robert President & CEO | 500,000 | $0 | 500,000 (Direct) | View |
| 2022-10-31 Option Award | 2022-11-02 7:08 pm | N/A 2032-10-30 | Eliem Therapeutics Inc. | ELYM | Lavelle Erin COO & CFO | 170,000 | $0 | 170,000 (Direct) | View |
| 2022-10-31 Option Award | 2022-11-02 7:06 pm | N/A 2032-10-30 | Eliem Therapeutics Inc. | ELYM | Bucher James B EVP and General Counsel | 95,000 | $0 | 95,000 (Direct) | View |